The implication of targeting PD-1:PD-L1 pathway in treating sepsis through immunostimulatory and anti-inflammatory pathways.

Autor:	Chen Y; School of Basic Medicine, Naval Medical University, Shanghai, China., Guo DZ; School of Basic Medicine, Naval Medical University, Shanghai, China., Zhu CL; Faculty of Anesthesiology, Changhai Hospital, Naval Medical University, Shanghai, China., Ren SC; Faculty of Anesthesiology, Changhai Hospital, Naval Medical University, Shanghai, China., Sun CY; Faculty of Anesthesiology, Changhai Hospital, Naval Medical University, Shanghai, China., Wang Y; Faculty of Anesthesiology, Changhai Hospital, Naval Medical University, Shanghai, China., Wang JF; Faculty of Anesthesiology, Changhai Hospital, Naval Medical University, Shanghai, China.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2023 Dec 13; Vol. 14, pp. 1323797. Date of Electronic Publication: 2023 Dec 13 (Print Publication: 2023).
DOI:	10.3389/fimmu.2023.1323797
Abstrakt:	Sepsis currently remains a major contributor to mortality in the intensive care unit (ICU), with 48.9 million cases reported globally and a mortality rate of 22.5% in 2017, accounting for almost 20% of all-cause mortality worldwide. This highlights the urgent need to improve the understanding and treatment of this condition. Sepsis is now recognized as a dysregulation of the host immune response to infection, characterized by an excessive inflammatory response and immune paralysis. This dysregulation leads to secondary infections, multiple organ dysfunction syndrome (MODS), and ultimately death. PD-L1, a co-inhibitory molecule expressed in immune cells, has emerged as a critical factor in sepsis. Numerous studies have found a significant association between the expression of PD-1/PD-L1 and sepsis, with a particular focus on PD-L1 expressed on neutrophils recently. This review explores the role of PD-1/PD-L1 in immunostimulatory and anti-inflammatory pathways, illustrates the intricate link between PD-1/PD-L1 and sepsis, and summarizes current therapeutic approaches against PD-1/PD-L1 in the treatment and prognosis of sepsis in preclinical and clinical studies. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Chen, Guo, Zhu, Ren, Sun, Wang and Wang.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu